A Phase 1, Open-label, Single-site, Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI
Phase of Trial: Phase I
Latest Information Update: 13 Sep 2017
At a glance
- Drugs NSI 566 (Primary)
- Indications Spinal cord injuries
- Focus Adverse reactions
- Sponsors Neuralstem
- 12 Apr 2017 According to a Neuralstem media release, the US FDA and the Institutional Review Board at the University of California San Diego have approved protocol amendment expanding this trial with a new cohort of four patients.
- 07 Apr 2017 Planned number of patients changed from 4 to 8.
- 07 Apr 2017 Planned End Date changed from 1 Mar 2016 to 1 Dec 2022.